Molecular Profile Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable JAK Inhibitor (Pan) Debio 0617B Preclinical - Patient cell culture Actionable In a preclinical study, Debio 0617B inhibited survival of a variety of patient-derived tumor cells in culture (PMID: 27439479). 27439479
Unknown unknown multiple myeloma not applicable JAK2 Inhibitor Carfilzomib + TG02 Phase I Actionable In a Phase I trial, TG02 in combination with Kyprolis (carfilzomib) resulted in an overall response rate of 27% (3/11) and durable stable disease in 27% (3/11) of multiple myeloma patients (Blood 2015 126:3052). detail...
Unknown unknown acute lymphocytic leukemia not applicable JAK2 Inhibitor TG02 Preclinical - Cell culture Actionable In a preclinical study, TG02 inhibited growth of acute lymphocytic leukemia cells in culture (PMID: 21860433). 21860433
Unknown unknown acute myeloid leukemia not applicable JAK2 Inhibitor TG02 Preclinical - Patient cell culture Actionable In a preclinical study, TG02 inhibited growth of acute myeloid leukemia cell lines and patient-derived acute myeloid leukemia cells in culture (PMID: 21860433). 21860433
Unknown unknown breast cancer not applicable JAK2 Inhibitor AJI-100 Preclinical - Pdx & cell culture Actionable In a preclinical study, AJI-100 induced apoptosis and inhibited cell growth of breast cancer cell lines and xenografts (PMID: 24930769). 24930769
Unknown unknown breast cancer not applicable JAK2 Inhibitor AJI-214 Preclinical - Cell culture Actionable In a preclinical study, AJI-214 inhibited invasion and induced apoptosis of breast cancer cells in culture (PMID: 24930769). 24930769
Unknown unknown colon adenocarcinoma not applicable JAK2 Inhibitor Epoetin beta + LFM-A13 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with the combination of Epoetin beta (erythropoietin beta) and LFM-A13 resulted in decreased BTK and AKT expression, reduced proliferation, and increased apoptosis compared to either agent alone in colon adenocarcinoma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 29160911). 29160911
Unknown unknown Advanced Solid Tumor not applicable JAK2 Inhibitor AT9283 Phase I Actionable In a Phase I clinical trial, AT9283 demonstrated safety and efficacy in patients with advanced solid tumors (PMID: 22015452). 22015452
Unknown unknown acute leukemia no benefit JAK2 Inhibitor AT9283 Phase Ib/II Actionable In a Phase I/II trial, AT9283 demonstrated tolerable toxicity but no clinical response in children with acute leukemia, although the trial failed to identify its primary endpoints due to poor recruitment and early termination (PMID: 27905678). 27905678
Unknown unknown prostate cancer not applicable JAK2 Inhibitor EC-70124 Preclinical - Cell line xenograft Actionable In a preclinical study, EC-70124 inhibited proliferation, colony formation, Stat3 activity, and NFkappaB activity in prostate cancer cells and prostate cancer stem cells in culture and inhibited tumor growth in cell line xenografts (PMID: 26826115). 26826115
Unknown unknown chronic myelomonocytic leukemia not applicable JAK2 Inhibitor - ATP competitive TG101209 Preclinical - Patient cell culture Actionable In a preclinical study, TG101209 inhibited colony formation of granulocytes and macrophages cultured from patients with chronic myelomonocytic leukemia (PMID: 27157043). 27157043
Unknown unknown ovarian cancer not applicable JAK2 Inhibitor - ATP competitive AZD1480 Preclinical Actionable In a preclinical study, AZD1480 inhibited cell proliferation of ovarian cancer cells with active Jak-Stat signaling in culture and blocked tumor growth in transgenic mouse models of ovarian cancer (PMID: 25646015). 25646015
Unknown unknown myelofibrosis not applicable JAK2 Inhibitor - ATP competitive SAR302503 Phase III Actionable In a Phase III trial, Fedratinib (SAR302503) demonstrated both clinical benefits and toxicity in myelofibrosis patients, resulting in symptom response rates at week 24 of 36% (33/91), 34% (31/91), and 7% (6/85) in the Fedratinib (SAR302503) 400 mg, 500 mg, and placebo groups, respectively (P<.001) (PMID: 26181658). 26181658
Unknown unknown T-cell leukemia no benefit JAK2 Inhibitor - ATP competitive AZD1208 + Ruxolitinib Preclinical Actionable In a preclinical study, Jakafi (ruxolitinib) and AZD1208 combination treatment did not inhibit proliferation of a T-cell leukemia cell line in culture (PMID: 26472029). 26472029
Unknown unknown pancreatic adenocarcinoma not applicable JAK2 Inhibitor - ATP competitive Capecitabine + Ruxolitinib Phase II Actionable In a Phase II trial, the combination of Jakafi (ruxolitinib) and Xeloda (capecitabine) did not prolong OS (median OS 4.5 vs. 4.3 months) in patients with pancreatic adenocarcinoma when compared to placebo plus Xeloda (capecitabine), however, prolonged OS (median OS 2.7 vs. 1.8 months) was observed in pancreatic adenocarcinoma patients with elevated levels of serum CRP (PMID: 26351344). 26351344
Unknown unknown myelodysplastic/myeloproliferative neoplasm not applicable JAK2 Inhibitor - ATP competitive Ruxolitinib Phase I Actionable In a Phase I trial, Jakafi (ruxolitinib) treatment demonstrated safety and preliminary efficacy in chronic myelomonocytic leukemia patients, resulted in a total response rate of 35% (7/20) and reduction of Stat5 signaling (PMID: 26858309). 26858309
Unknown unknown myelofibrosis not applicable JAK2 Inhibitor - ATP competitive Ruxolitinib FDA approved Actionable In a Phase III clinical trial that supported FDA approval, treatment with Jakafi (ruxolitinib) resulted in a decrease in spleen volume of greater than or equal to 35% in 41.9% of patients with intermediate or high-risk myelofibrosis, compared to 0.7% of patients treated with the placebo (PMID: 22474318). 22474318
Unknown unknown myelofibrosis not applicable JAK2 Inhibitor - ATP competitive XL019 Phase I Actionable In a Phase I trial, treatment with XL019 demonstrated clinical activity in 23% (7/30) of myelofibrosis patients, including 27% (6/22) of patients with JAK2 V617F and 13% (1/8) with wild-type JAK2, and resulted in responses in 10% (3/30) of patients, however, resulted in neurotoxicity and the trial was discontinued (PMID: 24374145; NCT00595829). 24374145
Unknown unknown pancreatic ductal adenocarcinoma not applicable JAK2 Inhibitor - ATP competitive Lestaurtinib Preclinical Actionable In preclinical studies, lestaurtinib has been shown to have an antitumor effect in xenograft models of pancreatic ductal adenocarcinoma (PMID: 10473107). 10473107
Clinical Trial Phase Therapies Title Recruitment Status